

Listing of Claims:

1. (canceled)

2. (presently amended) The method of claim + 8, wherein said neoplasm is derived from endodermal tissue.

3. (presently amended) The method of claim + 8, wherein said neoplasm is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.

4. (canceled)

5. (presently amended) The method of claim + 8, wherein said bodily fluid is selected from the group consisting of a CNS-derived bodily fluid, blood, serum, urine, saliva, sputum, lung effusion, and ascites fluid.

6. - 7. (canceled)

8. (previously amended) ~~The method of claim 6, A method for diagnosing a malignant neoplasm in a mammal, comprising contacting a bodily fluid from said mammal with an antibody or fragment thereof which binds to an human aspartyl (asparaginyl) beta-hydroxylase~~

(HAAH) polypeptide under conditions sufficient to form an antigen-antibody complex and
detecting the antigen-antibody complex, wherein an increase in antigen-antibody complex
indicates an increase in HAAH level compared to a normal noncancerous control, said increase
being indicative of a malignant neoplasm and wherein said monoclonal antibody is produced by
a hybridoma selected from the group consisting of hybridoma ATCC designation PTA 3383,
hybridoma ATCC designation PTA 3384, and hybridoma ATCC designation PTA 3385.

9. - 38. (canceled).

39. (presently amended) The method of claim 1 8, wherein said antibody is a single chain Fv molecule.

40. – 42. (canceled)

43. (presently amended) The method of claim 1 8, wherein the antigen-antibody complex is detected by a label selected from consisting of an enzymatic label, a fluorescent label, a chemiluminescent label, a radioactive label, and a dye label.

44. (canceled)

45. (previously amended) A method of diagnosing a malignant neoplasm in a mammal, comprising contacting a bodily tissue from said mammal with an antibody or fragment thereof which binds to a HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex, wherein an increase in HAAH compared

to a normal control indicates the presence of a malignant neoplasm and wherein said neoplasm is a hepatocellular carcinoma, wherein said antibody is produced by a hybridoma selected from the group consisting of hybridoma ATCC designation PTA 3383, hybridoma ATCC designation PTA 3384, and hybridoma ATCC designation PTA 3385.

46. (presently amended) The method of claim 4 8, wherein said neoplasm is a cholangiocarcinoma.

47. - 50 (canceled)

51. (presently amended) The method of claim 4 8, wherein said neoplasm is a glioblastoma.

52. (presently amended) The method of claim 4 8, wherein said neoplasm is a neuroblastoma.

53. – 54. (canceled).

55. (previously amended) A method of diagnosing a malignant neoplasm in a mammal, comprising contacting a bodily tissue from said mammal with an antibody or fragment thereof which binds to a HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex, wherein said antibody is produced by a hybridoma selected from the group consisting of hybridoma ATCC designation PTA 3383, hybridoma ATCC designation PTA 3384, and hybridoma ATCC designation PTA 3385 and

wherein an increase in HAAH compared to a normal control indicates the presence of a malignant neoplasm.

56. (previously amended) The method claim 51, wherein said antibody is produced by hybridoma ATCC designation 3383.

57. - 61. (canceled)

62. (newly added) The method of claim 45, wherein said neoplasm is derived from endodermal tissue.

63. (newly added) The method of claim 45, wherein said neoplasm is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.

64. (newly added) The method of claim 45, wherein said antibody is a single chain Fv molecule.

65. (newly added) The method of claim 45, wherein said neoplasm is a cholangiocarcinoma.

66. (newly added) The method of claim 45, wherein said neoplasm is a glioblastoma.

67. (newly added) The method of claim 45, wherein said neoplasm is a neuroblastoma.

68. (newly added) The method claim 45, wherein said antibody is produced by hybridoma ATCC designation 3383.
69. (newly added) The method of claim 55, wherein said neoplasm is derived from endodermal tissue.
70. (newly added) The method of claim 55, wherein said neoplasm is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.
71. (newly added) The method of claim 55, wherein said antibody is a single chain Fv molecule.
72. (newly added) The method of claim 55, wherein said neoplasm is a cholangiocarcinoma.
73. (newly added) The method of claim 55, wherein said neoplasm is a glioblastoma.
74. (newly added) The method of claim 55, wherein said neoplasm is a neuroblastoma.

Applicants: Wands *et al.*
U.S.S.N. 09/903,023

75. (newly added) The method claim 55, wherein said antibody is produced by hybridoma ATCC designation 3383.